Company intelligence / Profile preview

ImmunoMet Therapeutics

Houston, Texas, United Statesimmunomet.com ↗

Ownership: Private
Development stage: Phase 2

Overview

ImmunoMet’s lead molecule, lixumistat (IM156), is an orally bioavailable small molecule PC1 inhibitor that targets oxidative phosphorylation. It has completed Phase 1 studies demonstrating good tolerability and target inhibition. In a Phase 1b trial in advanced pancreatic cancer, lixumistat combined with gemcitabine/nab-paclitaxel showed promising safety at the recommended phase 2 dose of 400 mg QD. The compound has received Orphan Drug Designation for pancreatic cancer and glioblastoma multiforme. Additional programs are at earlier stages or preclinical development.[3][4][7]

Therapeutic areas: OtherOncologyImmunology
Modalities: Small molecules (notably biguanides)[1][4][7]
Industry: Biotech

Drug pipeline

2 assets

lixumistat

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships disclosed; collaborations with academic centers such as MD Anderson Cancer Center noted via clinical trials leadership.[7]Investors include HanAll Biopharma and Incon Co., Ltd., among others.[10]

Beyond the preview

Go deeper on ImmunoMet Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunoMet Therapeutics.

Explore the full profile